

Metabolic Disorders Therapeutics-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M376D1169D9EN.html>

Date: January 2018

Pages: 135

Price: US\$ 3,480.00 (Single User License)

ID: M376D1169D9EN

Abstracts

Report Summary

Metabolic Disorders Therapeutics-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Metabolic Disorders Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Metabolic Disorders Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Metabolic Disorders Therapeutics in EMEA, with company and product introduction, position in the Metabolic Disorders Therapeutics market
Market status and development trend of Metabolic Disorders Therapeutics by types and applications

Cost and profit status of Metabolic Disorders Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the EMEA Metabolic Disorders Therapeutics market as:

EMEA Metabolic Disorders Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Metabolic Disorders Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others

EMEA Metabolic Disorders Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases

EMEA Metabolic Disorders Therapeutics Market: Players Segment Analysis (Company and Product introduction, Metabolic Disorders Therapeutics Sales Volume, Revenue, Price and Gross Margin):

Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lilly
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
Amicus Therapeutics
Biopharma
Arena Pharmaceuticals
Astellas Pharma
Bionaturis

Diasome Pharmaceuticals
Lexicon Pharmaceuticals
Ligand Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF METABOLIC DISORDERS THERAPEUTICS

- 1.1 Definition of Metabolic Disorders Therapeutics in This Report
- 1.2 Commercial Types of Metabolic Disorders Therapeutics
 - 1.2.1 Metachromatic Leukodystrophy
 - 1.2.2 Globoid Leukodystrophy
 - 1.2.3 Hepatic Encephalopathy
 - 1.2.4 Others
- 1.3 Downstream Application of Metabolic Disorders Therapeutics
 - 1.3.1 Diabetes
 - 1.3.2 Obesity
 - 1.3.3 Hypercholesterolemia
 - 1.3.4 Lysosomal storage diseases
- 1.4 Development History of Metabolic Disorders Therapeutics
- 1.5 Market Status and Trend of Metabolic Disorders Therapeutics 2013-2023
 - 1.5.1 EMEA Metabolic Disorders Therapeutics Market Status and Trend 2013-2023
 - 1.5.2 Regional Metabolic Disorders Therapeutics Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Metabolic Disorders Therapeutics in EMEA 2013-2017
- 2.2 Consumption Market of Metabolic Disorders Therapeutics in EMEA by Regions
 - 2.2.1 Consumption Volume of Metabolic Disorders Therapeutics in EMEA by Regions
 - 2.2.2 Revenue of Metabolic Disorders Therapeutics in EMEA by Regions
- 2.3 Market Analysis of Metabolic Disorders Therapeutics in EMEA by Regions
 - 2.3.1 Market Analysis of Metabolic Disorders Therapeutics in Europe 2013-2017
 - 2.3.2 Market Analysis of Metabolic Disorders Therapeutics in Middle East 2013-2017
 - 2.3.3 Market Analysis of Metabolic Disorders Therapeutics in Africa 2013-2017
- 2.4 Market Development Forecast of Metabolic Disorders Therapeutics in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Metabolic Disorders Therapeutics in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Metabolic Disorders Therapeutics by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Metabolic Disorders Therapeutics in EMEA by Types

3.1.2 Revenue of Metabolic Disorders Therapeutics in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Metabolic Disorders Therapeutics in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Metabolic Disorders Therapeutics in EMEA by Downstream Industry

4.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Major Countries

4.2.1 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Europe

4.2.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Middle East

4.2.3 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Africa

4.3 Market Forecast of Metabolic Disorders Therapeutics in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS

5.1 EMEA Economy Situation and Trend Overview

5.2 Metabolic Disorders Therapeutics Downstream Industry Situation and Trend Overview

CHAPTER 6 METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Metabolic Disorders Therapeutics in EMEA by Major Players

6.2 Revenue of Metabolic Disorders Therapeutics in EMEA by Major Players

6.3 Basic Information of Metabolic Disorders Therapeutics by Major Players

6.3.1 Headquarters Location and Established Time of Metabolic Disorders

Therapeutics Major Players

6.3.2 Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 METABOLIC DISORDERS THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Novo Nordisk

7.1.1 Company profile

7.1.2 Representative Metabolic Disorders Therapeutics Product

7.1.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.2 Sanofi

7.2.1 Company profile

7.2.2 Representative Metabolic Disorders Therapeutics Product

7.2.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi

7.3 Merck

7.3.1 Company profile

7.3.2 Representative Metabolic Disorders Therapeutics Product

7.3.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck

7.4 AstraZeneca

7.4.1 Company profile

7.4.2 Representative Metabolic Disorders Therapeutics Product

7.4.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca

7.5 Eli Lilly

7.5.1 Company profile

7.5.2 Representative Metabolic Disorders Therapeutics Product

7.5.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly

7.6 AbbVie

7.6.1 Company profile

7.6.2 Representative Metabolic Disorders Therapeutics Product

7.6.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie

7.7 Actelion Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Metabolic Disorders Therapeutics Product

7.7.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals

7.8 Adocia

7.8.1 Company profile

7.8.2 Representative Metabolic Disorders Therapeutics Product

7.8.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia

7.9 Aegerion Pharmaceuticals

7.9.1 Company profile

7.9.2 Representative Metabolic Disorders Therapeutics Product

7.9.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals

7.10 Akros Pharma

7.10.1 Company profile

7.10.2 Representative Metabolic Disorders Therapeutics Product

7.10.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma

7.11 Alnylam Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Metabolic Disorders Therapeutics Product

7.11.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals

7.12 Amarin

7.12.1 Company profile

7.12.2 Representative Metabolic Disorders Therapeutics Product

7.12.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin

7.13 Amicus Therapeutics

7.13.1 Company profile

7.13.2 Representative Metabolic Disorders Therapeutics Product

7.13.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics

7.14 Biopharma

7.14.1 Company profile

- 7.14.2 Representative Metabolic Disorders Therapeutics Product
- 7.14.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma
- 7.15 Arena Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Metabolic Disorders Therapeutics Product
 - 7.15.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
- 7.16 Astellas Pharma
- 7.17 Bionaturis
- 7.18 Diasome Pharmaceuticals
- 7.19 Lexicon Pharmaceuticals
- 7.20 Ligand Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS

- 8.1 Industry Chain of Metabolic Disorders Therapeutics
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS

- 9.1 Cost Structure Analysis of Metabolic Disorders Therapeutics
- 9.2 Raw Materials Cost Analysis of Metabolic Disorders Therapeutics
- 9.3 Labor Cost Analysis of Metabolic Disorders Therapeutics
- 9.4 Manufacturing Expenses Analysis of Metabolic Disorders Therapeutics

CHAPTER 10 MARKETING STATUS ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy

- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Metabolic Disorders Therapeutics-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M376D1169D9EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M376D1169D9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970